Majority of EU member states say ‘no’ to INNs for biosimilars

By Zachary Brennan

- Last updated on GMT

Related tags: European union

Majority of EU member states say ‘no’ to INNs for biosimilars
Most EU member states “strongly supported” the idea that biosimilars should be closely aligned with their reference products, according to a summary of the European Commission’s pharmaceutical committee meeting released Monday.

A majority said that separate INNs (International Nonproprietary Names) for biosimilars would be “contrary to such an alignment​” as some member states said that these INNs could “undermine the trust of healthcare professionals and the public​.”

The same INN should be used for both the reference medicinal products and the biosimilar medicinal products​,” the committee wrote.

Some stakeholders, however, underlined the importance of the INN for the traceability of biosimilars and biologics and how to attribute an adverse reaction reports to the correct biological medicinal product.

But as far as traceability, member states in general “answered that both branded name and INN are reported, that batch number is often reported (frequency seems to vary between member states) and that it is not problematic to identify the biological medicinal products which are the subject of adverse reaction reports​.”

The battle over how biosimilars should be named has raised eyebrows across industry​ as some have said the discussion raises doubts on pharmacovigilance.

The EU move comes as the US FDA seems to remain on the fence over when biosimilars should be approved, even as the EU has approved at least 10. Pre-emptive state legislation​ also seems to be hampering the onslaught of biosimilars in the US.

But researchers at Frost & Sullivan​ recently indicated that politics and the FDA are not the only reasons that biosimilars have been slow to the US market. Scientifically ensuring the interoperability of biosimilars and biologics seems to be another key issue.

Related news

Show more

Related products

show more

Accelerating Time to IND with Pharma 4.0

Accelerating Time to IND with Pharma 4.0

Wheeler Bio | 22-Sep-2022 | Technical / White Paper

The future of the biopharmaceutical industry hinges on its adoption of 21st-century digital tools and automation.

dPCR Case Study

dPCR Case Study

CellCarta | 08-Aug-2022 | Case Study

Streamline your adoptive cell therapy program with digital PCR. Our team has a unique expertise in digital and quantitative PCR to support you in ensuring...

Seasonal Vaccine Manufacturing

Seasonal Vaccine Manufacturing

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

The production of seasonal vaccines, such as those for influenza, presents unique challenges to manufacturers due to the necessary time constraints resulting...

Consideration and Options for Prefilled Syringes

Consideration and Options for Prefilled Syringes

Baxter BioPharma Solutions | 16-Feb-2022 | Technical / White Paper

Convenience, product differentiation, and less waste are great reasons for developing a product in a prefilled syringe. Baxter’s whitepaper describes the...

Related suppliers

Follow us

Products

View more

Webinars